

ID NO: 19) Two prostate tumors (PNCap and DU0145), two ovarian tumors (HeLa and SK-OV-3), one lung tumor (LLC1) and one melanoma (B16) were tested. Cultured cells were treated with 1, 10, 50 or 100  $\mu$ M peptide. Results, depicted in Figure 4, show strong lytic activity against all tumors.

Please delete paragraph [0102], and replace it with the following paragraph:

**[0102]** As an example, melittin may be inactivated by attaching a phage filament, other peptide, or a biotin-streptavidin microbead, according to the following: Gly-Ile-Gly-Ala-Val-Leu-Lys-Val-Leu-Thr-Thr-Gly-Leu-Pro-Ala-Leu-Ile-Ser-Trp-Ile-Lys-Arg-Lys-Arg-Gln-[Gln-Gly-Ala-Ile\*Gly-Gln-Pro]-(X) (SEQ ID NOS 1 & 2, respectively), wherein \* denotes an MMP cleavage site and (X) is an inactivator. MMP cleavage will yield a melittin peptide with three additional amino acids on the C-terminus (Gly-Ala-Ile), which should not interfere with pore formation.

Please delete paragraph [0104], and replace it with the following paragraph:

**[0104]** The procytotoxin may further comprise a targeting sequence, such as Biotin-Gly-Gly-Cys-Asp-Cys-Arg-Gly-Asp-Cys-Phe-Cys (SEQ ID NO: 20) (RGD-4C)  $\alpha$  $\beta$ <sub>3</sub> integrin targeting peptide or biotin-anti-fibronectin ED-B antibody.

**In the Claims:**

Please amend the claims as follows:

15. (Amended) The procytotoxin of claim 14, wherein said cytolytic peptide comprises the following structure: Gly-Ile-Gly-Ala-Val-Leu-Lys-Val-Leu-Thr-Thr-Gly-Leu-Pro-Ala-Leu-Ile-Ser-Trp-Ile-Lys-Arg-Lys-Arg-Gln-[Gln-Gly-Ala-Ile-Gly-Gln-Pro] (residues 1-32 of SEQ ID NOS 1 or 2).

18. (Amended) The procytotoxin of claim 14, wherein said cytolytic peptide comprises the following structure: Gly-Ile-Gly-Ala-Val-Leu-Lys-Val-Leu-Thr-Thr-Gly-Leu-Pro-Ala-Leu-Ile-Ser-Trp-Ile-Lys-Arg-Lys-Arg-Gln-[Gln- Ser-Ser-Phe(or Tyr)-Tyr-Ser-Gly(or Ser)] (residues 1-32 of SEQ ID NOS 3 or 4).

36. (Amended) The method of claim 35, wherein said cytolytic peptide comprises the following structure: Gly-Ile-Gly-Ala-Val-Leu-Lys-Val-Leu-Thr-Thr-Gly-Leu-Pro-Ala-Leu-Ile-Ser-Trp-Ile-Lys-Arg-Lys-Arg-Gln-[Gln-Gly-Ala-Ile-Gly-Gln-Pro] (residues 1-32 of SEQ ID NOS 1 or 2).

38. (Amended) The method of claim 35, wherein said cytolytic peptide comprises the following structure: Gly-Ile-Gly-Ala-Val-Leu-Lys-Val-Leu-Thr-Thr-Gly-Leu-Pro-Ala-Leu-Ile-Ser-Trp-Ile-Lys-Arg-Lys-Arg-Gln-[Gln-Ser-Ser-Phe(or Tyr)-Tyr-Ser-Gly(or Ser)] (residues 1-32 of SEQ ID NOS 3 or 4).

54. (Amended) The method of claim 53, wherein said cytolytic peptide comprises the following structure: Gly-Ile-Gly-Ala-Val-Leu-Lys-Val-Leu-Thr-Thr-Gly-Leu-Pro-Ala-Leu-Ile-Ser-Trp-Ile-Lys-Arg-Lys-Arg-Gln-[Gln-Gly-Ala-Ile-Gly-Gln-Pro] (residues 1-32 of SEQ ID NOS 1 or 2).

57. (Amended) The method of claim 53, wherein said cytolytic peptide comprises the following structure: Gly-Ile-Gly-Ala-Val-Leu-Lys-Val-Leu-Thr-Thr-Gly-Leu-Pro-Ala-Leu-Ile-Ser-Trp-Ile-Lys-Arg-Lys-Arg-Gln-[Gln- Ser-Ser-Phe(or Tyr)-Tyr-Ser-Gly(or Ser)] (residues 1-32 of SEQ ID NOS 3 or 4).